Brian Leyland-Jones
Overview
Explore the profile of Brian Leyland-Jones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
5991
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Solomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Saintigny P, et al.
Cancer Med
. 2022 Mar;
11(14):2790-2800.
PMID: 35307972
Background: The Worldwide Innovative Network (WIN) Consortium has developed the Simplified Interventional Mapping System (SIMS) to better define the cancer molecular milieu based on genomics/transcriptomics from tumor and analogous normal...
2.
Sicklick J, Kato S, Okamura R, Patel H, Nikanjam M, Fanta P, et al.
Genome Med
. 2021 Oct;
13(1):155.
PMID: 34607609
Background: Malignancies are molecularly complex and become more resistant with each line of therapy. We hypothesized that offering matched, individualized combination therapies to patients with treatment-naïve, advanced cancers would be...
3.
Fraser Symmans W, Yau C, Chen Y, Balassanian R, Klein M, Pusztai L, et al.
JAMA Oncol
. 2021 Sep;
7(11):1654-1663.
PMID: 34529000
Importance: Residual cancer burden (RCB) distributions may improve the interpretation of efficacy in neoadjuvant breast cancer trials. Objective: To compare RCB distributions between randomized control and investigational treatments within subtypes...
4.
Bossuyt V, Lau R, Young B, Howe J, Zhao F, Leyland-Jones B, et al.
Clin Chem
. 2021 Aug;
67(9):1240-1248.
PMID: 34374711
Background: The sensitivity to endocrine therapy assay (SET2,3) predicts treatment outcomes in Stage II-III breast cancer. SET2,3 measures transcription related to estrogen and progesterone receptors (SETER/PR index) and the molecular...
5.
Dey N, Aske J, Lin X, Sun Y, Leyland-Jones B, Friedman L, et al.
Am J Cancer Res
. 2021 Jul;
11(6):2867-2892.
PMID: 34249433
HER2 signaling network and its complex relationship with the PI3K-AKT-mTOR pathway explain the acquired resistance to anti-HER2 therapy observed in clinics. Such complexity has been clinically evident from the limited...
6.
Bohan S, Sicklick J, Kato S, Okamura R, Miller V, Leyland-Jones B, et al.
Oncologist
. 2020 Sep;
25(11):e1803-e1806.
PMID: 32949172
Background: Precision oncology uses molecular profiling of tumors to identify biomarker-tailored therapies for patients in the hope of improving outcomes. Typically, only a minority of patients receives evaluable matched treatment....
7.
Willis S, Polydoropoulou V, Sun Y, Young B, Tsourti Z, Karlis D, et al.
JCO Precis Oncol
. 2020 Sep;
2.
PMID: 32913993
Purpose: The Herceptin Adjuvant study is an international multicenter randomized trial that compared 1 or 2 years of trastuzumab given every 3 weeks with observation in women with human epidermal...
8.
Willis S, Sun Y, Abramovitz M, Fei T, Young B, Lin X, et al.
JCO Precis Oncol
. 2020 Sep;
1.
PMID: 32913979
Purpose: Identification of single-gene biomarkers that are prognostic of outcome can shed new insights on the molecular mechanisms that drive breast cancer and other cancers. Methods: Exploratory analysis of 20,464...
9.
Hertz D, Kidwell K, Douglas J, Viale G, Leyland-Jones B, Regan M, et al.
Pharmacogenomics
. 2020 Jul;
21(13):899-902.
PMID: 32723153
No abstract available.
10.
Yee D, DeMichele A, Yau C, Isaacs C, Fraser Symmans W, Albain K, et al.
JAMA Oncol
. 2020 Jul;
6(9):1355-1362.
PMID: 32701140
Importance: Pathologic complete response (pCR) is a known prognostic biomarker for long-term outcomes. The I-SPY2 trial evaluated if the strength of this clinical association persists in the context of a...